Dr. Reddy's to buy Betapharm in $570M deal
Dr. Reddy's has inked a deal to buy Germany's Betapharm for $570 million. News of the pact immediately sent Dr. Reddy's shares up about 10 percent as investors cheered the news of the buyout. Betapharm is Germany's fourth-largest generics drug manufacturer and a plum acquisition for an Indian player like Dr. Reddy's. Ranbaxy was reportedly an aggressive bidder for the European company.
- read this Red Herring article
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
